416 related articles for article (PubMed ID: 28980759)
1. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
[TBL] [Abstract][Full Text] [Related]
2. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.
Stufano F; Baronciani L; Mane-Padros D; Cozzi G; Faraudo S; Peyvandi F
Haemophilia; 2018 Jan; 24(1):156-161. PubMed ID: 29168270
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
Favaloro EJ; Mohammed S
Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease.
Stufano F; Baronciani L; Bucciarelli P; Boscarino M; Colpani P; Pagliari MT; Peyvandi F
Haemophilia; 2020 Mar; 26(2):298-305. PubMed ID: 32107842
[TBL] [Abstract][Full Text] [Related]
5. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease.
Verfaillie CJ; De Witte E; Devreese KM
Int J Lab Hematol; 2013 Oct; 35(5):555-65. PubMed ID: 23551532
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.
Cabrera N; Moret A; Caunedo P; Cid AR; Vila V; España F; Aznar JA
Haemophilia; 2013 Nov; 19(6):920-5. PubMed ID: 23730809
[TBL] [Abstract][Full Text] [Related]
7. Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.
Sagheer S; Rodgers S; Yacoub O; Dauer R; Mcrae S; Duncan E
Haemophilia; 2016 May; 22(3):e200-7. PubMed ID: 27076201
[TBL] [Abstract][Full Text] [Related]
8. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
9. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
11. Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease.
Popov J; Zhukov O; Ruden S; Zeschmann T; Sferruzza A; Sahud M
Clin Chem; 2006 Oct; 52(10):1965-7. PubMed ID: 16887898
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies.
Costa-Pinto J; Pérez-Rodríguez A; del C Goméz-del-Castillo M; Lourés E; Rodríguez-Trillo A; Batlle J; López-Fernández MF
Haemophilia; 2014 Jul; 20(4):559-67. PubMed ID: 25077350
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
[TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
16. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
[TBL] [Abstract][Full Text] [Related]
17. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB).
Favaloro EJ; Mohammed S
Methods Mol Biol; 2017; 1646():417-433. PubMed ID: 28804845
[TBL] [Abstract][Full Text] [Related]
18. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
[TBL] [Abstract][Full Text] [Related]
20. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]